The narrower net loss is a positive headline, but the one-time nature of the revenue catch-up and the CBPd-171 delay create uncertainty. Monitor for updated CBPd-171 guidance and any data readouts from the FHD-909 Phase 1 trial, which are the primary catalysts.
Drug in focus
FHTX drug pipeline →FHD-909
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Unknown — the drug is in early Phase 1 dose-escalation. Assuming successful development, a potential approval would be several years away (likely 2029+).
- Next catalyst
- None dated
What to watchMonitor for any announced Phase 1 data readout date or interim results from the FHD-909 dose-escalation trial, which would be the next major catalyst. Also watch the December 2026 Lilly collaboration term expiration for potential restructuring or milestone news. The stock's ~144% implied upside to analyst targets reflects optimism about the platform, but early-stage clinical risk remains substantial.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $5.57entry
- T+1 · 3mo ago +8.98%α +8.37% · $6.07
- T+5 · 3mo ago +16.52%α +15.30% · $6.49
- T+20 · 3mo ago −12.57%α −13.17% · $4.87
- T+60 · 18d ago −62.66%α −60.99% · $2.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narrower than the $17.9M loss in Q2 2025, driven by a $14.2M cumulative catch-up adjustment in collaboration revenue from the Lilly agreement. The company highlighted its FHD-909 Phase 1 trial advancing as planned and a new immunology/inflammation program, but disclosed a delay in the CBPd-171 timeline due to a CRO operational issue. The narrower net loss is a positive, but the one-time revenue adjustment and the CBPd-171 delay temper the outlook for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss narrowed to $7.2M in Q2 2026 from $17.9M in Q2 2025, largely due to a $14.2M cumulative catch-up adjustment in collaboration revenue.
- Collaboration revenue surged to $16.1M from $7.6M YoY, driven by the catch-up adjustment tied to the scheduled expiration of the Lilly research term in December 2026.
- Cash, cash equivalents, and marketable securities stood at $167.6M, providing runway into the first half of 2028.
- The CBPd-171 (FHT-171) timeline has been delayed due to an unexpected operational issue at a third-party CRO; updated guidance is pending.
- FHD-909 Phase 1 dose-escalation trial is on track with NSCLC as the primary target population.
- The company is accelerating a novel oral small molecule in immunology and inflammation toward an IND in 2027.
Financial Impact
Net loss improved by $10.7M YoY, but this was driven by a $14.2M non-recurring catch-up adjustment. Cash burn remains significant at ~$7.2M per quarter from operations.
Risk Factors
- CBPd-171 timeline delay could signal broader CRO/operational risks.
- Lilly collaboration research term expires in December 2026, creating a potential revenue cliff.
- Pre-revenue biotech with no approved products; stock is highly sensitive to pipeline updates and cash runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-053817 |
| Document: a2026augustfoghorninvest.htm | 0001628280-26-053817 |
| Document: fhtx-20260806.htm | 0001628280-26-053817 |
| Document: 0001628280-26-053817-index-headers.html | 0001628280-26-053817 |
| Document: 0001628280-26-053817-index.html | 0001628280-26-053817 |
| Document: 0001628280-26-053817.txt | 0001628280-26-053817 |
| 8-K Data (Synthetic) | 0001628280-26-053817 |
Track record
9 reports on FHTX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +31.85% at T+5 after the Oct 1, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $1.81 Now $1.79 −0.83% settles Dec 15
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $2.04 Now $1.79 −12.25% settles Dec 8
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $1.97 to $2.12 Now $1.79 −9.14% ▲ +7.36% +10.26% vs SPY
- Oct 5, 20266w ago SC 13G/A Neutral 4/10 Entry $1.97 to $2.13 Now $1.79 −9.14% ▲ +8.12% +11.30% vs SPY
- Oct 1, 20266w ago 8-K Bearish 7/10 Entry $2.92 to $2.09 Now $1.79 +38.70% ▲ +28.42% +29.13% vs SPY
- Aug 6, 202614w ago 8-K Mixed 5/10 Viewing Entry $5.57 to $4.87 Now $1.79 −67.86% ▼ −12.57% −13.17% vs SPY
- May 7, 202627w ago 8-K Neutral 3/10 Entry $4.20 to $3.64 Now $1.79 −57.38% ▼ −13.33% −16.47% vs SPY
- Apr 21, 202629w ago Press Release Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
- Apr 21, 202629w ago 8-K Bullish 7/10 Entry $5.39 to $3.60 Now $1.79 −66.79% ▼ −33.21% −36.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers